Peerview Oncology & Hematology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/UUY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Approaches to managing patients with hepatocellular carcinoma (HCC) are undergoing renovation! A recent wave of improved therapeutic regimens, including immunotherapy/anti-VEGF combinations (eg, atezolizumab and bevacizumab), dual immunotherapy combinations (ie, durvalumab-tremelimumab), and next-generation TKIs (ie, lenvatinib) has been introduced in the upfront setting. Recent additions to the second-line setting have delivered improved options for patients with HCC including immune checkpoint inhibitors (eg, pembrolizumab and tislelizumab) and multikinase inhibitors (ie, cabozantinib and regorafenib). Emerging data on other up-and-coming targeted platforms are forthcoming, including evidence for perioperative applications in earlier disease settings. With all of these developments, how should we update our clinical rulebooks for treating HCC? This activity, based on a recent